- Home
- NVT vs EXEL Comparison
NVT vs EXEL Comparison
Compare NVT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- EXEL
- Stock Information
- Founded
- NVT 1903
- EXEL 1994
- Country
- NVT United Kingdom
- EXEL United States
- Employees
- NVT N/A
- EXEL N/A
- Industry
- NVT Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVT Industrials
- EXEL Health Care
- Exchange
- NVT Nasdaq
- EXEL Nasdaq
- Market Cap
- NVT 11.5B
- EXEL 11.6B
- IPO Year
- NVT N/A
- EXEL 2000
- Fundamental
- Price
- NVT $70.28
- EXEL $40.37
- Analyst Decision
- NVT Strong Buy
- EXEL Buy
- Analyst Count
- NVT 9
- EXEL 18
- Target Price
- NVT $70.33
- EXEL $39.59
- AVG Volume (30 Days)
- NVT 1.6M
- EXEL 2.6M
- Earning Date
- NVT 08-05-2025
- EXEL 08-05-2025
- Dividend Yield
- NVT 1.15%
- EXEL N/A
- EPS Growth
- NVT 1.65
- EXEL 237.58
- EPS
- NVT 3.49
- EXEL 2.20
- Revenue
- NVT $3,083,300,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- NVT $18.99
- EXEL $9.37
- Revenue Next Year
- NVT $8.97
- EXEL $11.05
- P/E Ratio
- NVT $20.00
- EXEL $18.12
- Revenue Growth
- NVT 15.90
- EXEL 24.49
- 52 Week Low
- NVT $41.71
- EXEL $21.36
- 52 Week High
- NVT $81.55
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- NVT 64.91
- EXEL 42.39
- Support Level
- NVT $67.40
- EXEL $41.03
- Resistance Level
- NVT $71.52
- EXEL $42.07
- Average True Range (ATR)
- NVT 1.62
- EXEL 0.95
- MACD
- NVT -0.03
- EXEL -0.42
- Stochastic Oscillator
- NVT 84.34
- EXEL 12.85
About NVT nVent Electric plc
nVent is a leading global provider of electrical connection and protection solutions that touches a broad range of end markets including infrastructure, industrial, commercial, and residential. NVent designs, manufacturers, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.